Most Recent
The maker of Ugg footwear has successfully opposed an application by an Australian shoe seller to register a trade mark containing the word 'ugg', but a delegate has warned the company it does not have an exclusive right to the descriptive word.
The Australian Competition and Consumer Commission is investigating claims by suppliers that government bodies have diverted supplies of COVID-19 rapid antigen tests, as the regulator continues its crackdown on reported price gouging amid a test shortage.
The Australian Securities and Investments Commission is challenging a ruling that threw out half the criminal charges against direct bank Members Equity, arguing the statute of limitations doesn't apply to serious corporate misconduct.
BHP's policy requiring Queensland workers to be vaccinated against COVID-19 and show proof of the jab has withstood a challenge from mining unions that claimed the rule was unreasonable and breached the Privacy Act.
An appeals court has unanimously rejected the Commissioner of Taxation’s latest bid to block Shell’s $2.3 billion tax deduction for the cost of exploration activities conducted as part of the Browse LNG project off the coast of Western Australia.
The world's largest macadamia grower has launched an appeal of an IP Australia decision that found its logo mark was deceptively similar to US confectionary giant Mars’ trade marks for its flagship candy M&Ms.
Embattled investment group Mayfair 101 is challenging a judge's decision last month to slug it with a $30 million penalty for engaging in misleading and deceptive advertising.
The Australian Federal Police is cracking down on COVID-19 rapid antigen test price gouging, deploying a zero-tolerance strike team to investigate “outrageous” markups referred by the Australian Competition and Consumer Commission.
A law firm has escaped an order for costs sought by a Melbourne city council that argued the firm had turned a blind eye to a client’s lack of credibility in an unfair dismissal case.
Israeli drug company Neurim Pharmaceuticals has won an eight month extension to apply for a grace period for its melatonin tablet patent to treat children with autism spectrum disorder after Australian company Generic Partners lost its "inherently implausible" opposition to the patent.